The front runners in the game of drug delivery include small molecule and large molecule drugs, but there is another class that lands right in between: peptides.

Research into new peptide therapeutics continues at a steady pace, with more than 150 peptides in clinical development and another 400–600 peptides undergoing preclinical studies. Due to their low toxicity, easy synthesis, rapid elimination, and lower off-target side effects, a rapidly expanding number of peptide-based protein inhibitors are now emerging in the commercial marketplace.

​Our approach to design new peptide-based inhibitors is highly innovative. Using a novel computational strategy, we are in a unique position to leverage high-confidence protein interaction data and artificial intelligence to evolve novel peptides that “disrupt” activity and/or interactions of proteins that drive disease. As natural biomolecules of biological regulation, proteins and peptides have exquisite target specificity and, by leveraging natural interaction data, we are able to avoid the off-target effects that plague small chemicals. NuvoBio’s development platform, DARWIN AI, holds potential in accelerating peptide design and helping to refine efforts in target validation and screening. By moving the experiments to a virtual environment, and expedite the discovery of novel peptide-inhibitors.